medigraphic.com
Colegio de Medicina Interna de México.

2007, Number 5

<< Back Next >>

Med Int Mex 2007; 23 (5)

Acute fatty liver of pregnancy and beta-oxidation disorders

Duarte MJ, Díaz MS, Lee ECVE, Castro BJ, Velásquez DV

Language: Spanish
References: 117
Page: 424-435
PDF size: 174.70 Kb.


ABSTRACT

Acute fatty liver of pregnancy (AFLP) is a serious disorder of the third trimester with high maternal and perinatal morbidity and mortality. Over the past decade, several clinical observations have demonstrated an association between these maternal syndromes and a recessively inherited fatty acid oxidation disorder, long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Many women who carried LCHAD-deficient fetuses developed maternal liver disease. Today we have made significant progress in understanding the molecular basis for this fetal-maternal interaction.


REFERENCES

  1. Sheehan HL. Jaundice in pregnancy. Am J Obstet Gynecol 1961;81:427-40.

  2. Stander H, Cadden B. Acute yellow atrophy of the liver in pregnancy. Am J Obstet Gynecol 1934;28:61-9.

  3. Monga M, Katz AR. Acute fatty liver in the second trimester. Obstet Gynecol 1999;93:811-3.

  4. Vigil-De Gracia P. Acute fatty liver and HELLP syndrome: two distinct pregnancy disorders. Int J Obstet Gynaecol 2001;73(3):215-20.

  5. Vigil-De Gracia P, Lavergne JA. Acute fatty liver of pregnancy. Int J Obstet Gynaecol 2001;72(2):193-5.

  6. Knox TA, Olans LB. Liver disease in pregnancy. N Engl J Med 1985;313:367-70.

  7. Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its relationship to tetracycline therapy. Am J Med 1965;33:359-77.

  8. Pockros PJ, Peters RL, Reynolds TB. Idiopathic fatty liver of pregnancy: findings in ten cases. Medicine (Baltimore) 1984;63:1-11.

  9. Davidson KM, Simpson LL, Knox TA, D’Alton ME. Acute fatty liver of pregnancy in triplet gestation. Obstet Gynecol 1998;91:806-8.

  10. Gastro MA, Fassett MJ, Reynolds TB, Shaw KJ, Goodwin TM. Reversible peripartum liver failure: a new perspective on the diagnosis, treatment, and cause of acute fatty liver of pregnancy, based on 28 consecutive cases. Am J Obstet Gynecol 1991;181:389-95.

  11. Jwayyed SM, Blanda M, Kubina M. Acute fatty liver of pregnancy. J Emerg Med 1999;17:673-7.

  12. Buytaert IM, Elewaut AG, Van Kets HE. Early occurrence of acute fatty liver in pregnancy. Am J Gastroenterol 1996;91:603-4.

  13. Bacq Y. Acute fatty liver of pregnancy. Semin Perinatol 1998;22:134-40.

  14. Przepiesc J, Redzko S, Urban J. Acute fatty liver of pregnancy: treatment, prognosis, rules of management. Ginekol Pol 1999;70:205-9.

  15. Ibdah JA, Bennett MJ, Rinaldo P, Zhao Y, et al. A fetal fattyacid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999;340:1723-31.

  16. Kamijo T, Wanders RJ, Saudubray JM, Aoyama T, et al. Mitochondrial trifunctional protein deficiency: catalytic heterogeneity of the mutant enzyme in two patients. J Clin Invest 1994;93:1740-7.

  17. Brackett JC, Sims HF, Rinaldo P, Shapiro S, et al. Two a subunit donor splice site mutations cause human trifunctional protein deficiency. J Clin Invest 1995;95:2076-82.

  18. Ibdah JA, Tein I, Dionisi-Vici C, Bennett MJ, et al. Mild trifunctional protein deficiency is associated with progressive neuropathy and myopathy and suggests a novel genotypephenotype correlation. J Clin Invest 1998;102:1193-9.

  19. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Ann Rev Physiol 2002;64:477-502.

  20. Spiekerkoetter U, Sun B, Khuchua Z, Bennett MJ, Strauss AW. Molecular and phenotypic heterogeneity in mitochondrial trifunctional protein deficiency due to b-subunit mutations. Hum Mutat 2003;21:598-607.

  21. Blish KR, Ibdah JA. Maternal heterozygosity for a mitochondrial trifunctional protein mutation as a cause for liver disease in pregnancy. Med Hypotheses 2005:64:96-100.

  22. Suzuki S, Watanabe S, Araki T. Acute fatty liver of pregnancy at 23 weeks of gestation. Br J Obstet Gynaecol 2001;108:223-4.

  23. Castro MA, Fassett MJ. Reversible peripartum liver failure: a new perspective on the diagnosis, treatment, and cause of acute fatty liver of pregnancy, based on 28 consecutive cases. Am J Obstet Gynecol 1999;181:389-95.

  24. Grimbert S, Fromentry B, Fisch C. Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevence to development of acute fatty liver of pregnancy. Hepatology 1993;17:628-37.

  25. Grimbert S, Fisch C, Deschamps D, Berson A, et al. Effects of female sex hormones on mitochondria: possible role in acute fatty liver of pregnancy. Am J Physiol 1995;268:G107-15.

  26. Schoeman MN, Batey RG, Wilcken B. Recurrent acute fatty liver of pregnancy associated with a fatty acid oxidation defect in the off-spring. Gastroenterology 1991;100:544-8.

  27. Browning MF. Fetal fatty acid oxidation defects and maternal liver disease in pregnancy. Obstet Gynecol 2006;107:115-20.

  28. Visconti M, Manes G, Giannattasio F, Uomo G. Recurrence of acute fatty liver of pregnancy. J Clin Gastroenterol 1995;21:243-5.

  29. MacLean MA, Cameron AD, Cumming GP, Murphy K, et al. Recurrence of acute fatty liver of pregnancy. Br J Obstet Gynaecol 1994;101:453-4.

  30. Barton JR, Sibai BM, Mabie WC, Shanklin DR. Recurrent acute fatty liver of pregnancy. Am J Obstet Gynecol 1990;163:534-8.

  31. Yang Z, Zhao Y, Bennett MJ, Strauss AW, Ibdah JA. Fetal genotypes and pregnancy outcomes in 35 families with mitochondrial trifunctional protein mutations. Am J Obstet Gynecol 2002;187:715-20.

  32. Yang Z, Yamada J, Zhao Y, Strauss AW, Ibdah JA. Prospective screening for pediatric mitochondrial trifunctional protein defects in pregnancies complicated by liver disease. JAMA 2002;288:2163-6.

  33. Blish KR, Ibdah JA. Maternal heterozygosity for a mitochondrial trifunctional protein mutation as a cause for liver disease in pregnancy Med Hypotheses 2005;64:96-100.

  34. Tyni T, Ekholm E, Pihko H. Pregnancy complications are frequent in long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Am J Obstet Gynecol 1998;178:603-8.

  35. Sibai BM, Ramadan MK, Usta I, Salama M, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993;169:1000-6.

  36. Sibai BM, Ramadan MK, Chari RS, Friedman SA, et al. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 1995;172:125-9.

  37. Steingrub JS. Pregnancy-associated severe liver dysfunction. Crit Care Clin 2004;20:763-76.

  38. Rinaldo P, Raymond K, Al-Odaib A, Bennett MJ. Clinical and biochemical features of fatty acid oxidation disorders. Curr Opin Pediatr 1998;10:615-21.

  39. Woolf AJ, Johnston AW, Stokes JF, Roberton NR. Acute liver failure in pregnancy: case report with survival of mother and child. Br J Obstet Gynaecol 1964;71:914-8.

  40. Fesenmeier MF, Coppage KH. Acute fatty liver of pregnancy in 3 tertiary care centers. Am J Obstet Gynecol 2005;192:1416-9.

  41. Burroughs AK. Idiopathic acute fatty liver of pregnancy in 12 patients. Q J Med 1982;51:481-97.

  42. Sims HF. The molecular basis of pediatric long chain 3- hydroxyacyl-CoA deshydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci USA 1995;92:841-5.

  43. Yang W, Shen Z. Acute fatty liver of pregnancy: an experience in diagnosis and management of eight cases. Department of Obstetrics & Gynecology, First Affiliated Hospital to Suzhou Medical College. Suzhou, PR China 1998;5(4).

  44. Rolfes DB, Ishak KG. Acute fatty liver of pregnancy: a clinicopathologic study of 35 cases. Hepatology 1985;5:1149-58.

  45. Minakami H, Oka N, Sato T, Tamada T, et al. Preeclampsia: a microvesicular fat disease of the liver?. Am J Obstet Gynecol 1988;159:1042-7.

  46. Riely CA. Acute fatty liver of pregnancy. Semin Liver Dis 1987;7(1):292-4.

  47. Purdie JM, Walters BNJ. Acute fatty liver of pregnancy: clinical features and diagnosis. Aust NZ J Obstet Gynaecol 1988;28(1):62-67.

  48. Knox TA, Olans LB. Liver disease in pregnancy. N Engl J Med 1996;335:569-76.

  49. Riely CA, Latham PS, Romero R, Duffy TB. Acute fatty liver of pregnancy: a reassessment based on observations in nine patients. Ann Intern Med 1987;106:703-6.

  50. Barton J, Riely CA, Adamec TA, Shanklin DR, et al. Hepatic histopathologic condition does not correlate with laboratory abnormalities in HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count). Am J Obstet Gynecol 1992;167:1538-43.

  51. Dani R, Mendes GS, Medeiros JL, Peret FJ, Nunes A. Study of the liver changes occurring in preeclampsia and their possible pathogenic connection with acute fatty liver of pregnancy. Am J Gastroenterol 1996;91:292-4.

  52. Ibdah JA, Yang Z. Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genet Metab 2000;71:182-9.

  53. Yang Z. Prospective screening for pediatric mitochondrial trifunctional proteins defects in pregnancy complicated by liver disease. JAMA 2002;288:2163-6.

  54. Vida JA. A fetal fatty acid-oxidation disorder as a cause of liver disease in pregnant woman. N Eng J Med 1999;340:1723-31.

  55. Treem WR. Acute fatty liver of pregnancy and long-chain 3 hydroxyacyl-CoA deshydrogenase deficiency. Hepatology 1994;14:339-45.

  56. Rahman TM. Severe hepatic dysfunction in pregnancy. Q J Med 2002;95:343-57.

  57. Benjaminov FS. Liver disease in pregnancy. Am J Gastroenterol 2004;99:2479-88.

  58. Reyes H, Sandoval L, Wainstein A, Ribalta J, et al. Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients. Gut 1994;35:101-6.

  59. Mabie WC. Acute fatty liver of pregnancy. Crit Care Clin 1991;7:799-808.

  60. Sibai BM, Kustermann L, Velasco J. Current understanding of severe preeclampsia, pregnancy associated hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, hemolysis, elevated liver enzymes, and low platelet syndrome, and postpartum acute renal failure: Different clinical syndromes or just different names?. Curr Opin Nephrol Hypertens 1994;3:436-45.

  61. Usta IM, Barton JR, Amon EA, Gonzalez A, Sibai BM. Acute fatty liver of pregnancy: an experience in the diagnosis and management of fourteen cases. Am J Obstet Gynecol 1994;171:1342-7.

  62. Schoeman MN, Batey RG, Wilcken B. Recurrent acute fatty liver of pregnancy associated with a fatty acid oxidation defect in the off-spring. Gastroenterology 1991;100:544-8.

  63. Treem WR, Rinaldo P, Hale DE, Stanley CA, et al. Acute fatty liver of pregnancy and long-chain 3- hydroxyacyl–coenzyme-A dehydrogenase deficiency. Hepatology 1994;19:339-45.

  64. Grimbert S, Fisch C, Deschamps D, Berson A, et al. Effects of female sex hormones on liver mitochondria in non-pregnant female mice: a possible role in acute fatty liver of pregnancy. Am J Physiol 1995;268:107-15.

  65. Den Boer MEJ, Wanders RJA, Morris AAM, Ijlst L, et al. Long-chain 3-hydroxyacyl-coa dehydrogenase deficiency: clinical presentation and follow-up of 50 patients. Pediatrics 2002;109:99-104.

  66. Rakheja D, Bennett MJ, Rogers BB. Long-chain 3-hydroxyacyl- coenzyme a dehydrogenase deficiency: a molecular and biochemical review. Lab Invest 2002;82:815-24.

  67. Shekhawat P, Bennett MJ, Sadovsky Y, Nelson DM, et al. Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. Am J Phys Endocrinol Metab 2003;284(6):E1098-105.

  68. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Ann Rev Physiol 2002;64:477-502.

  69. Sim KG, Hammond J, Wilcken B. Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. Clin Chim Acta 2002;323:37-58.

  70. Rinaldo P, Raymond K, Al-Odaib A, Bennett MJ. Clinical and biochemical features of fatty acid oxidation disorders. Curr Opin Pediatr 1998;10:615-21.

  71. Sims HF, Brackett JC, Powell CK, Treem WR, et al. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci USA 1995;92:841-5.

  72. Jackson S, Kler RS, Barlett K, Briggs H, et al. Combined enzyme defect of mitochondrial fatty acid oxidation. J Clin Invest 1992;90:1219-25.

  73. Kamijo T, Aoyama A, Komiyama A, Hashimoto T. Structural analysis of cDNAs for subunits of human mitochondrial fatty acid b-oxidation trifunctional protein. Biochem Biophys Res Commun 1994;199:818-25.

  74. Ushikubo S, Aoyama T, Kamijo T, Wanders RJA, et al. Molecular characterization of mitochondrial trifunctional protein deficiency: formation of the enzyme complex is important for stabilization of both and b-subunits. Am J Hum Genet 1996;58:979-88.

  75. IJ1st L, Ruiter JPN, Hoovers JMN, Jakobs ME, Wanders RJA. Common missense mutation G1528C mutation in longchain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Clin Invest 1996;98:1028-33.

  76. Wanders RJA, Duran M, IJ1st L, De Jager JP, et al. Sudden infant death and long-chain 3-hydroxyacyl-CoA dehydrogenase. Lancet 1989;2:52-53.

  77. Pollitt RJ. Disorders of mitochondrial long-chain fatty acid oxidation. J Inher Metab Dis 1995;18:473-90.

  78. IJ1st L, Uskikubo S, Kamijo T, Hashimoto T, et al. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: high frequency of the G1528C mutation with no apparent correlation with the clinical phenotype. J Inheritd Metab Dis 1985;18:241-4.

  79. Hagenfeldt N, Venizelos N, Dobeln U. Clinical and biochemical presentation of long chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J Inheritd Metab Dis 1985;18:245-8.

  80. Tyni T, Palotie A, Viinikka L, Valanne L, et al. Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency with the G1528C mutation: clinical presentation in 13 patients. J Pediatr 1997;130:67-76.

  81. Kamijo T, Wanders RJA, Saudubray JM, Aoyama T, et al. Mitochondrial trifunctional protein deficiency. J Clin Invest 93:1740-7.

  82. Wilcken B, Leung KC, Hammond J, Kamath R, Leonard JV. Pregnancy and fetal long-chain 3-hydroxyacyl coenzyme A dehydrogenase deficiency. Lancet 1993;341:407-8.

  83. Iljst L, Ruiter JP, Hoovers JM, Jakobs ME, Wanders RJ. Common missense mutation G1528C in long-chain 3-hydroxyacyl- CoA dehydrogenase deficiency: characterization and expression of the mutant protein, mutation analysis on genomic DNA and chromosomal localization of the mitochondrial trifunctional protein a subunit gene. J Clin Invest 1996;98:1028-33.

  84. Yang Z, Zhao Y, Bennett MJ, Strauss AW, Ibdah JA. Fetal genotypes and pregnancy outcomes in 35 families with mitochondrial trifunctional protein mutations. Am J Obstet Gynecol 2002;187:715-20.

  85. Gregersen N, Andresen BS, Bross P. Prevalent mutations in fatty acid oxidation disorders: diagnostic considerations. Eur J Pediatr 2000;159(Suppl):213-8.

  86. IJlst L, Ushikubo S, Kamijo T. Long-chain 3-hydroxyacyl- CoA dehydrogenase deficiency: high frequency of the G1528C mutation with no apparent correlation with the clinical phenotype. J Inheritd Metab Dis 1995;18:241-4.

  87. IJlst L, Wanders RJA, Ushikubo S, Kamijo T, Hashimoto T. Molecular basis of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: identification of the major disease-causing mutation in the alpha-subunit of the mitochondrial trifunctional protein. Biochim Biophys Acta 1994;1215:347-50.

  88. IJlst L, Ruiter JPN, Hoovers JMN, Jakobs ME, Wanders RJA. Common missense mutation G1528C in long-chain 3-hydroxyacyl- CoA dehydrogenase deficiency—characterization and expression of the mutant protein, mutation analysis on genomic DNA and chromosomal localization of the mitochondrial trifunctional protein alpha subunit gene. J Clin Invest 1996;98:1028-33.

  89. Yang Z. Fetal genotypes and pregnancy outcomes in 35 families with mitochondrial trifunctional protein mutations. Am J Obstet Gynecol 2002;187:715-20.

  90. Tyni T, Ekholm E. Pregnancy complications are frequent in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Obstet Gynecol 1998;178:603-8.

  91. Yang Z, Zhao Y, Bennett MJ, Strauss AW, Ibdah JA. Fetal genotypes and pregnancy outcomes in 35 families with mitochondrial trifunctional protein mutations. Am J Obstet Gynecol 2002;187:715-20.

  92. Baldwin GS, Murphy VJ, Yang Z, Hashimoto T. Binding of non-steroidal anti-inflammatory drugs to the a-subunit of the trifunctional protein of long chain fatty acid oxidation. J Pharmacol Exp Ther 1998;286:1110-4.

  93. Kamijo T, Wanders RJ, Saudubray JM, Aoyama T, et al. Mitochondrial trifunctional protein deficiency: catalytic heterogeneity of the mutant enzyme in two patients. J Clin Invest 1994;93:1740-7.

  94. Brackett JC, Sims HF, Rinaldo P, Shapiro S, et al. Two a subunit donor splice site mutations cause human trifunctional protein deficiency. J Clin Invest 1995;95:2076-82.

  95. Rinaldo P, Matern D, Bennett MJ. Fatty acid oxidation disorders. Annu Rev Physiol 2002;64:477-502.

  96. Spiekerkoetter U, Sun B, Khuchua Z, Bennett MJ, Strauss AW. Molecular and phenotypic heterogeneity in mitochondrial trifunctional protein deficiency due to b-subunit mutations. Hum Mutat 2003;21:598-607.

  97. Treem WR, Rinaldo P, Hale DE. Acute fatty liver of pregnancy and long-chain 3-hydroxyacylcoenzyme A dehydrogenase deficiency. Hepatology 1994;19:339-45.

  98. Treem WR, Shoup ME, Hale DE. Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelet syndrome, and long chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency. Am J Gastroenterol 1996;91:2293-300.

  99. Chalmers RA, Stanley CA, English N, Wigglesworth JS. Mitochondrial carnitine- acylcarnitine translocase deficiency presenting as sudden neonatal death. J Pediatr 1997;131:220-5.

  100. Bonnefont JP, Haas R, Wolff J, Thuy LP, et al. Deficiency of carnitine palmitoyltransferase I. J Child Neurol 1989;4:198-203.

  101. Innes AM, Seargeant LE, Balachandra K, Roe CR, et al. Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy. Pediatr Res 2000;47:43-5.

  102. Nelson J, Lewis B, Walters B. The HELLP syndrome associated with fetal medium-chain acyl-CoA dehydrogenase deficiency. J Inheritd Metab Dis 2000;23:518-9.

  103. Walter JH. Inborn errors of metabolism and pregnancy. J Inheritd Metab Dis 2000;23:229-36.

  104. Matern M. Acute fatty liver of pregnancy associated with shortchain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 2001;138:585-8.

  105. Baldwin GS. Do NSAIDs contribute to acute fatty liver of pregnancy?. Med Hypotheses 2000;54(5):846-9.

  106. Deschamps D, Fisch C, Fromenty B, et al. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye’s syndrome. J Pharmacol Exp Ther 1991;259:894-904.

  107. Shekhawat P, Bennett MJ, Sadovsky Y, Nelson DM, et al. Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. Am J Physiol Endocrinol Metab 2003;284(6):1098-105.

  108. Yang Z, Yamada J, Zhao Y, Strauss AW, Ibdah JA. Prospective screening for pediatric mitochondrial trifunctional protein defects in pregnancies complicated by liver disease. JAMA 2002;288:2163-6.

  109. Blish KR, Ibdah JA. Maternal heterozygosity for a mitochondrial trifunctional protein mutation as a cause for liver disease in pregnancy. Med Hypotheses 2005;64:96-100.

  110. Yang Z, Zhao Y, Bennett MJ, Strauss AW, Ibdah JA. Fetal genotypes and pregnancy outcomes in 35 families with mitochondrial trifunctional protein mutations. Am J Obstet Gynecol 2002;187:715-20.

  111. Welsh A. Hyperemesis, gastrointestinal and liver disorders in pregnancy. Curr Obstet Gynaecology 2005;15:123-31.

  112. Grimbert S, Fisch C, Deschamps D, Berson A, et al. Effects of female sex hormones on liver mitochondria in non-pregnant female mice: a possible role in acute fatty liver of pregnancy. Am J Physiol 1995;268:107-15.

  113. Fukushima K, Ueno Y. Lack of common mutation in the alfa-subunit of the mitochondrial trifunctional protein and the polymorphism of CYP2E1 in three Japanese women with acute fatty liver of pregnancy/HELLP syndrome. Hepatology Research 2004;30:226-31.

  114. Schattenberg JM, Wang Y, Rigoli RM, Koop DR, Czaja MJ. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology 2004;39(2):444-55.

  115. Coffey CG. Cellular bases for the lipid-related aspects of preeclampsia. Med Hypotheses 2003;60(5):716-9.

  116. Benjaminov FS. Liver desease in pregnancy. Am J Gastroenterol 2004;99:2479-88.

  117. Ibdah JA, Yang Z. Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Gen Metabolism 2000;71:182-9.




2020     |     www.medigraphic.com